| Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of … C Rödel, T Liersch, H Becker, R Fietkau, W Hohenberger, T Hothorn, ... The lancet oncology 13 (7), 679-687, 2012 | 784 | 2012 |
| First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous5-fluorouracil/leucovorin J Cassidy, C Twelves, E Van Cutsem, P Hoff, E Bajetta, M Boyer, R Bugat, ... Annals of oncology 13 (4), 566-575, 2002 | 647 | 2002 |
| Vascular endothelial growth factor, a possible paracrine growth factor in human acute myeloid leukemia W Fiedler, U Graeven, S Ergun, S Verago, N Kilic, M Stockschläder, ... Blood, The Journal of the American Society of Hematology 89 (6), 1870-1875, 1997 | 607 | 1997 |
| S3-Leitlinie „Kolorektales Karzinom “–Aktualisierung 2008. Ergebnis einer evidenzbasierten Konsensuskonferenz (8.–9. Juni 2007) W Schmiegel, A Reinacher-Schick, D Arnold, U Graeven, V Heinemann, ... Z gastroenterol 46 (8), 799-840, 2008 | 534* | 2008 |
| Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials E Van Cutsem, PM Hoff, P Harper, RM Bukowski, D Cunningham, ... British journal of cancer 90 (6), 1190-1197, 2004 | 530 | 2004 |
| Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final … C Rödel, U Graeven, R Fietkau, W Hohenberger, T Hothorn, D Arnold, ... The Lancet Oncology 16 (8), 979-989, 2015 | 525 | 2015 |
| Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis I Schwarte-Waldhoff, OV Volpert, NP Bouck, B Sipos, SA Hahn, ... Proceedings of the National Academy of Sciences 97 (17), 9624-9629, 2000 | 395 | 2000 |
| Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO … R Porschen, HT Arkenau, S Kubicka, R Greil, T Seufferlein, W Freier, ... Journal of Clinical Oncology 25 (27), 4217-4223, 2007 | 364 | 2007 |
| German S3-guideline" Diagnosis and treatment of esophagogastric cancer" M Moehler, SE Al-Batran, T Andus, M Anthuber, J Arends, D Arnold, ... Zeitschrift fur Gastroenterologie 49 (4), 461-531, 2011 | 304 | 2011 |
| Outcome according to KRAS-, NRAS-and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO … DP Modest, I Ricard, V Heinemann, S Hegewisch-Becker, W Schmiegel, ... Annals of Oncology 27 (9), 1746-1753, 2016 | 297 | 2016 |
| Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non … S Hegewisch-Becker, U Graeven, CA Lerchenmüller, B Killing, ... The Lancet Oncology 16 (13), 1355-1369, 2015 | 280 | 2015 |
| S3-Leitlinie „Kolorektales Karzinom”–Aktualisierung 2008 W Schmiegel, A Reinacher-Schick, D Arnold, U Graeven, V Heinemann, ... Zeitschrift für Gastroenterologie 46 (08), 799-840, 2008 | 264 | 2008 |
| Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final … C Rodel, U Graeven, R Fietkau, W Hohenberger, T Hothorn, D Arnold, ... Lancet Oncol 16 (8), 979-89, 2015 | 249 | 2015 |
| 5-Fluorouracil induces arterial vasocontractions T Südhoff, MD Enderle, M Pahlke, C Petz, C Teschendorf, U Graeven, ... Annals of Oncology 15 (4), 661-664, 2004 | 196 | 2004 |
| The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic … C Buske, E Hoster, M Dreyling, H Eimermacher, H Wandt, B Metzner, ... Leukemia 23 (1), 153-161, 2009 | 194 | 2009 |
| Chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for patients with locally advanced rectal cancer: long-term results of the CAO/ARO … E Fokas, A Schlenska-Lange, B Polat, G Klautke, GG Grabenbauer, ... JAMA oncology 8 (1), e215445-e215445, 2022 | 187 | 2022 |
| S3-guideline colorectal cancer version 1.0 C Pox, S Aretz, SC Bischoff, U Graeven, M Hass, P Heußner, ... Zeitschrift fur Gastroenterologie 51 (8), 753-854, 2013 | 187 | 2013 |
| Transforming Growth Factor β Production and Responsiveness in Normal Human Melanocytes and Melanoma Cells U Rodeck, A Bossler, U Graeven, FE Fox, PC Nowell, C Knabbe, C Kari Cancer research 54 (2), 575-581, 1994 | 184 | 1994 |
| Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation DW Beelen, E Haralambie, H Brandt, G Linzenmeier, KD Muller, ... | 168 | 1992 |
| Tumor regression grading after preoperative chemoradiotherapy as a prognostic factor and individual-level surrogate for disease-free survival in rectal cancer E Fokas, P Ströbel, R Fietkau, M Ghadimi, T Liersch, GG Grabenbauer, ... JNCI: Journal of the National Cancer Institute 109 (12), djx095, 2017 | 148 | 2017 |
